Bayer CropScience: Recommends a dividend of Rs 5.50 for FY14, buyIndiaNotes.com
Bayer CropScience has recommended a dividend of Rs. 5.50/- per share of Rs. 10/- each for the year ended March 31, 2014. At CMP of Rs.1805.00, the stock P/E ratio is at 21.07 x FY15E and 19.34 x FY16E respectively. Buy for a target of Rs.1985.00
Exide Ind: Net sales grows 17.51% to Rs19123.60 mn; Maintain buyIndiaNotes.com
Exide Industries' Net sales registered a growth of 17.51% to Rs.19123.60 million for the quarter ended June 30th 2014 as against Rs.15412.00 million for the corresponding quarter last year. Buy for a target of Rs.180.00.
Finolex Ind: Q1 Net profit ramps up by 121.68%; Maintain buyIndiaNotes.com
Finolex's net profit for the quarter ramps up by 121.68% to Rs. 502.03 million from Rs. 226.47 million, when compared with the prior year period. Investors are recommended to buy the stock for a price target of Rs319 for medium to long term investment.
Bayer CropScience: Recommends a dividend of Rs 5.50 for FY14, buyIndiaNotes.com
Bayer CropScience has recommended a dividend of Rs. 5.50/- per share of Rs. 10/- each for the year ended March 31, 2014. At CMP of Rs.1805.00, the stock P/E ratio is at 21.07 x FY15E and 19.34 x FY16E respectively. Buy for a target of Rs.1985.00
Exide Ind: Net sales grows 17.51% to Rs19123.60 mn; Maintain buyIndiaNotes.com
Exide Industries' Net sales registered a growth of 17.51% to Rs.19123.60 million for the quarter ended June 30th 2014 as against Rs.15412.00 million for the corresponding quarter last year. Buy for a target of Rs.180.00.
Finolex Ind: Q1 Net profit ramps up by 121.68%; Maintain buyIndiaNotes.com
Finolex's net profit for the quarter ramps up by 121.68% to Rs. 502.03 million from Rs. 226.47 million, when compared with the prior year period. Investors are recommended to buy the stock for a price target of Rs319 for medium to long term investment.
Sanofi India: Q2CY14 net rises 12.30%, maintain buyIndiaNotes.com
Sanofi's net profit jumps up by 12.30% and stands at Rs. 575.00 million against Rs. 512.00 million same period previous year. Revenue of the company registered a growth of 16.25%. Maintain buy for medium to long term investment.
Excel Crop Care: Net profit ramps up by 214% in FY14, buyIndiaNotes.com
Net profit ramps up by 214% for FY14 and stood at Rs. 672.51 million as against Rs. 214.24 million for the period of previous year. Operating Profit also increased by 90% to Rs. 1084.81 million. Buy for a target of Rs810.
Shilpa Medicare: Buy for medium to long term investmentIndiaNotes.com
At CMP of Rs. 467.40, the stock P/E ratio is at 17.33 x FY15E and 14.73 x FY16E respectively. Investors are recommended to buy the stock for a price target of Rs.514.00 for medium to long term investment.
how to sell pi coins in all Africa Countries.DOT TECH
Yes. You can sell your pi network for other cryptocurrencies like Bitcoin, usdt , Ethereum and other currencies And this is done easily with the help from a pi merchant.
What is a pi merchant ?
Since pi is not launched yet in any exchange. The only way you can sell right now is through merchants.
A verified Pi merchant is someone who buys pi network coins from miners and resell them to investors looking forward to hold massive quantities of pi coins before mainnet launch in 2026.
I will leave the telegram contact of my personal pi merchant to trade with.
@Pi_vendor_247
BYD SWOT Analysis and In-Depth Insights 2024.pptxmikemetalprod
Indepth analysis of the BYD 2024
BYD (Build Your Dreams) is a Chinese automaker and battery manufacturer that has snowballed over the past two decades to become a significant player in electric vehicles and global clean energy technology.
This SWOT analysis examines BYD's strengths, weaknesses, opportunities, and threats as it competes in the fast-changing automotive and energy storage industries.
Founded in 1995 and headquartered in Shenzhen, BYD started as a battery company before expanding into automobiles in the early 2000s.
Initially manufacturing gasoline-powered vehicles, BYD focused on plug-in hybrid and fully electric vehicles, leveraging its expertise in battery technology.
Today, BYD is the world’s largest electric vehicle manufacturer, delivering over 1.2 million electric cars globally. The company also produces electric buses, trucks, forklifts, and rail transit.
On the energy side, BYD is a major supplier of rechargeable batteries for cell phones, laptops, electric vehicles, and energy storage systems.
how to sell pi coins at high rate quickly.DOT TECH
Where can I sell my pi coins at a high rate.
Pi is not launched yet on any exchange. But one can easily sell his or her pi coins to investors who want to hold pi till mainnet launch.
This means crypto whales want to hold pi. And you can get a good rate for selling pi to them. I will leave the telegram contact of my personal pi vendor below.
A vendor is someone who buys from a miner and resell it to a holder or crypto whale.
Here is the telegram contact of my vendor:
@Pi_vendor_247
The secret way to sell pi coins effortlessly.DOT TECH
Well as we all know pi isn't launched yet. But you can still sell your pi coins effortlessly because some whales in China are interested in holding massive pi coins. And they are willing to pay good money for it. If you are interested in selling I will leave a contact for you. Just telegram this number below. I sold about 3000 pi coins to him and he paid me immediately.
Telegram: @Pi_vendor_247
Empowering the Unbanked: The Vital Role of NBFCs in Promoting Financial Inclu...Vighnesh Shashtri
In India, financial inclusion remains a critical challenge, with a significant portion of the population still unbanked. Non-Banking Financial Companies (NBFCs) have emerged as key players in bridging this gap by providing financial services to those often overlooked by traditional banking institutions. This article delves into how NBFCs are fostering financial inclusion and empowering the unbanked.
US Economic Outlook - Being Decided - M Capital Group August 2021.pdfpchutichetpong
The U.S. economy is continuing its impressive recovery from the COVID-19 pandemic and not slowing down despite re-occurring bumps. The U.S. savings rate reached its highest ever recorded level at 34% in April 2020 and Americans seem ready to spend. The sectors that had been hurt the most by the pandemic specifically reduced consumer spending, like retail, leisure, hospitality, and travel, are now experiencing massive growth in revenue and job openings.
Could this growth lead to a “Roaring Twenties”? As quickly as the U.S. economy contracted, experiencing a 9.1% drop in economic output relative to the business cycle in Q2 2020, the largest in recorded history, it has rebounded beyond expectations. This surprising growth seems to be fueled by the U.S. government’s aggressive fiscal and monetary policies, and an increase in consumer spending as mobility restrictions are lifted. Unemployment rates between June 2020 and June 2021 decreased by 5.2%, while the demand for labor is increasing, coupled with increasing wages to incentivize Americans to rejoin the labor force. Schools and businesses are expected to fully reopen soon. In parallel, vaccination rates across the country and the world continue to rise, with full vaccination rates of 50% and 14.8% respectively.
However, it is not completely smooth sailing from here. According to M Capital Group, the main risks that threaten the continued growth of the U.S. economy are inflation, unsettled trade relations, and another wave of Covid-19 mutations that could shut down the world again. Have we learned from the past year of COVID-19 and adapted our economy accordingly?
“In order for the U.S. economy to continue growing, whether there is another wave or not, the U.S. needs to focus on diversifying supply chains, supporting business investment, and maintaining consumer spending,” says Grace Feeley, a research analyst at M Capital Group.
While the economic indicators are positive, the risks are coming closer to manifesting and threatening such growth. The new variants spreading throughout the world, Delta, Lambda, and Gamma, are vaccine-resistant and muddy the predictions made about the economy and health of the country. These variants bring back the feeling of uncertainty that has wreaked havoc not only on the stock market but the mindset of people around the world. MCG provides unique insight on how to mitigate these risks to possibly ensure a bright economic future.
The Evolution of Non-Banking Financial Companies (NBFCs) in India: Challenges...beulahfernandes8
Role in Financial System
NBFCs are critical in bridging the financial inclusion gap.
They provide specialized financial services that cater to segments often neglected by traditional banks.
Economic Impact
NBFCs contribute significantly to India's GDP.
They support sectors like micro, small, and medium enterprises (MSMEs), housing finance, and personal loans.
Poonawalla Fincorp and IndusInd Bank Introduce New Co-Branded Credit Cardnickysharmasucks
The unveiling of the IndusInd Bank Poonawalla Fincorp eLITE RuPay Platinum Credit Card marks a notable milestone in the Indian financial landscape, showcasing a successful partnership between two leading institutions, Poonawalla Fincorp and IndusInd Bank. This co-branded credit card not only offers users a plethora of benefits but also reflects a commitment to innovation and adaptation. With a focus on providing value-driven and customer-centric solutions, this launch represents more than just a new product—it signifies a step towards redefining the banking experience for millions. Promising convenience, rewards, and a touch of luxury in everyday financial transactions, this collaboration aims to cater to the evolving needs of customers and set new standards in the industry.
how to swap pi coins to foreign currency withdrawable.DOT TECH
As of my last update, Pi is still in the testing phase and is not tradable on any exchanges.
However, Pi Network has announced plans to launch its Testnet and Mainnet in the future, which may include listing Pi on exchanges.
The current method for selling pi coins involves exchanging them with a pi vendor who purchases pi coins for investment reasons.
If you want to sell your pi coins, reach out to a pi vendor and sell them to anyone looking to sell pi coins from any country around the globe.
Below is the contact information for my personal pi vendor.
Telegram: @Pi_vendor_247
USDA Loans in California: A Comprehensive Overview.pptxmarketing367770
USDA Loans in California: A Comprehensive Overview
If you're dreaming of owning a home in California's rural or suburban areas, a USDA loan might be the perfect solution. The U.S. Department of Agriculture (USDA) offers these loans to help low-to-moderate-income individuals and families achieve homeownership.
Key Features of USDA Loans:
Zero Down Payment: USDA loans require no down payment, making homeownership more accessible.
Competitive Interest Rates: These loans often come with lower interest rates compared to conventional loans.
Flexible Credit Requirements: USDA loans have more lenient credit score requirements, helping those with less-than-perfect credit.
Guaranteed Loan Program: The USDA guarantees a portion of the loan, reducing risk for lenders and expanding borrowing options.
Eligibility Criteria:
Location: The property must be located in a USDA-designated rural or suburban area. Many areas in California qualify.
Income Limits: Applicants must meet income guidelines, which vary by region and household size.
Primary Residence: The home must be used as the borrower's primary residence.
Application Process:
Find a USDA-Approved Lender: Not all lenders offer USDA loans, so it's essential to choose one approved by the USDA.
Pre-Qualification: Determine your eligibility and the amount you can borrow.
Property Search: Look for properties in eligible rural or suburban areas.
Loan Application: Submit your application, including financial and personal information.
Processing and Approval: The lender and USDA will review your application. If approved, you can proceed to closing.
USDA loans are an excellent option for those looking to buy a home in California's rural and suburban areas. With no down payment and flexible requirements, these loans make homeownership more attainable for many families. Explore your eligibility today and take the first step toward owning your dream home.
Turin Startup Ecosystem 2024 - Ricerca sulle Startup e il Sistema dell'Innov...Quotidiano Piemontese
Turin Startup Ecosystem 2024
Una ricerca de il Club degli Investitori, in collaborazione con ToTeM Torino Tech Map e con il supporto della ESCP Business School e di Growth Capital
Exploring Abhay Bhutada’s Views After Poonawalla Fincorp’s Collaboration With...beulahfernandes8
The financial landscape in India has witnessed a significant development with the recent collaboration between Poonawalla Fincorp and IndusInd Bank.
The launch of the co-branded credit card, the IndusInd Bank Poonawalla Fincorp eLITE RuPay Platinum Credit Card, marks a major milestone for both entities.
This strategic move aims to redefine and elevate the banking experience for customers.
how can I sell pi coins after successfully completing KYCDOT TECH
Pi coins is not launched yet in any exchange 💱 this means it's not swappable, the current pi displaying on coin market cap is the iou version of pi. And you can learn all about that on my previous post.
RIGHT NOW THE ONLY WAY you can sell pi coins is through verified pi merchants. A pi merchant is someone who buys pi coins and resell them to exchanges and crypto whales. Looking forward to hold massive quantities of pi coins before the mainnet launch.
This is because pi network is not doing any pre-sale or ico offerings, the only way to get my coins is from buying from miners. So a merchant facilitates the transactions between the miners and these exchanges holding pi.
I and my friends has sold more than 6000 pi coins successfully with this method. I will be happy to share the contact of my personal pi merchant. The one i trade with, if you have your own merchant you can trade with them. For those who are new.
Message: @Pi_vendor_247 on telegram.
I wouldn't advise you selling all percentage of the pi coins. Leave at least a before so its a win win during open mainnet. Have a nice day pioneers ♥️
#kyc #mainnet #picoins #pi #sellpi #piwallet
#pinetwork
what is the best method to sell pi coins in 2024DOT TECH
The best way to sell your pi coins safely is trading with an exchange..but since pi is not launched in any exchange, and second option is through a VERIFIED pi merchant.
Who is a pi merchant?
A pi merchant is someone who buys pi coins from miners and pioneers and resell them to Investors looking forward to hold massive amounts before mainnet launch in 2026.
I will leave the telegram contact of my personal pi merchant to trade pi coins with.
@Pi_vendor_247
Buy Makers Laboratories, company growing rapidly with strong thrust on branded generics
1. CMP 89.85
Target Price 103.00
ISIN: INE987A01010
AUG 10th
2015
MAKERS LABORATORIES LTD
Result Update (PARENT BASIS): Q1 FY16
BUYBUYBUYBUY
Index Details
Stock Data
Sector Pharmaceuticals
BSE Code 506919
Face Value 10.00
52wk. High / Low (Rs.) 89.85/29.25
Volume (2wk. Avg. Q.) 13000
Market Cap (Rs. in mn.) 441.79
Annual Estimated Results (A*: Actual / E*: Estimated)
YEARS FY15A FY16E FY17E
Net Sales 649.14 714.05 771.18
EBITDA 45.94 58.77 63.37
Net Profit 23.53 26.75 29.33
EPS 4.79 5.44 5.96
P/E 18.78 16.52 15.06
Shareholding Pattern (%)
As on June-15 As on March-15
PROMOTER 58.37 58.37
FIIs 0.00 0.00
DIIs 0.00 0.00
OTHERS 41.63 41.63
1 Year Comparative Graph
MAKERS LABORATORIES LTD BSE SENSEX
SYNOPSIS
Makers Laboratories Ltd is a rapidly growing
Indian Pharmaceutical company with a strong
thrust on Branded Generics.
In Q1 FY16, Net profit stood at Rs. 13.16 million
an increase of 135.42% against Rs. 5.59 million in
the corresponding quarter of previous year.
The company’s net sales registered 2.75%
increase in Q1 FY16 and stood at Rs. 174.07
million from Rs. 169.41 million over the
corresponding quarter of previous year.
During the quarter operating profit is Rs. 24.04
million as against Rs. 13.11 million in the
corresponding period of the previous year, an
increase of 83.37%.
The company has reported an EPS of Rs. 2.68 for
the 1st quarter of FY16 as against an EPS of Rs.
1.14 in the corresponding quarter of the previous
year, grew by 135.42%.
Profit before tax (PBT) at Rs. 20.22 million in Q1
FY16 compared to Rs. 8.47 million in Q1 FY15,
registered a growth of 138.72%.
Net Sales and PAT of the company are expected to
grow at a CAGR of 6% and 5% over 2014 to
2017E respectively.
PEER GROUPS CMP MARKET CAP EPS P/E (X) P/BV(X) DIVIDEND
Company Name (Rs.) Rs. in mn. (Rs.) Ratio Ratio (%)
Makers Laboratories Ltd 89.85 441.79 4.79 18.78 1.79 10.00
Tyche Industries Ltd 56.45 578.60 1.88 30.03 1.27 5.00
Mangalam Drugs & Organics Ltd 80.35 1058.90 7.24 11.10 3.61 0.00
Granules India Ltd 115.10 23595.70 5.33 21.59 5.54 50.00
2. QUARTERLY HIGHLIGHTS (PARENT BASIS)
Results updates- Q1 FY16,
Makers Laboratories Limited is a rapidly growing
Indian Pharmaceutical company with a strong thrust
on Branded Generics, has reported its financial
results for the quarter ended 30th June, 2015.
The company has achieved a turnover of Rs. 174.07 million for the 1st quarter of the current year 2015-16 as
against Rs. 169.41 million in the corresponding quarter of the previous year. EBITDA of Rs. 24.04 million in Q1
FY16, an increase of 83.37% against the corresponding period of last year. In Q1 FY16, net profit of Rs. 13.16
million against Rs. 5.59 million in the corresponding quarter of the previous year. The company has reported an
EPS of Rs. 2.68 for the 1st quarter as against an EPS of Rs. 1.14 in the corresponding quarter of the previous year.
Break up of Expenditure
Rs. In million June-15 June-14 % CHNG
Net Sales 174.07 169.41 2.75
PAT 13.16 5.59 135.42
EPS 2.68 1.14 135.42
EBITDA 24.04 13.11 83.37
Break up of Expenditure
(Rs in millions)
Q1 FY16 Q1 FY15
%
CHNG
Cost of materials
consumed
53.25 65.70 -19%
Purchases of stock-in-trade 69.40 75.68 -8%
Employee benefit expense 19.26 16.90 14%
Depreciation/Amortization
Expense
3.06 3.74 -18%
Other expenses 33.39 35.48 -6%
3. COMPANY PROFILE
Makers Laboratories Limited is a rapidly growing Indian Pharmaceutical company with a strong thrust on
Branded Generics. The company’s product portfolio covers a wide range of General Health Therapeutic segments.
The company’s top formulation brands are Duramol (Paracetamol), Artemak-AB (α-β Arteether), Loroquin
(Chloroquine), Nimuwin (Nimuselide), Coffwin (Anti cough Range) and Exylin (Amoxycillin range).
Makers Laboratories Limited operate on a PAN India basis with strong distribution network of 20 Consignment
Agents, catering to more than 1500 Stockist, 1,00,000 Doctors and 2,00,000 Retailers. Each of company’s
Consignment Agent has their own stockist network, which expand the reach of company’s products to the
common man. This network of Stockist is enhanced further by strong field staff.
Makers Laboratories Limited fulfills an important Corporate Social Responsibility by offering business
opportunities to young Indian. Makers Laboratories train them to become Business Associates. The company’s
products are propagated in both the urban and rural areas of India by such trained Business Associates.. Makers
Laboratories Limited believes in Quality & ensure that all requisite quality norms are adhered to. Makers
Laboratories Limited makes life easier by offering high quality products at affordable prices.
4. FINANCIAL HIGHLIGHT (PARENT BASIS) (A*- Actual, E* -Estimations & Rs. In Millions)
Balance Sheet as at March 31, 2014 -2017E
FY14A FY15A FY16E FY17E
I. EQUITY AND LIABILITIES:
A. Shareholders’ Funds
a) Share Capital 49.17 49.17 49.17 49.17
b) Reserves and Surplus 179.86 197.08 223.83 253.16
Sub-Total-Net worth 229.03 246.25 273.00 302.33
B. Non-Current Liabilities:
a) Deferred Tax Liabilities [Net] 7.52 6.54 6.15 5.84
b) Other Long Term Liabilities 40.03 37.74 39.25 40.43
c) Long Term Provisions 1.28 1.81 2.06 2.27
Sub-Total-Long term liabilities 48.83 46.09 47.46 48.54
C. Current Liabilities:
a) Short-term borrowings 21.19 7.97 7.17 6.60
b) Trade Payables 104.61 75.49 79.26 82.44
c) Other Current Liabilities 3.72 3.79 4.02 4.18
d) Short Term Provisions 2.82 11.37 13.42 15.29
Sub-Total-Current Liabilities 132.34 98.62 103.87 108.51
TOTAL-EQUITY AND LIABILITIES (A+B+C) 410.20 390.96 424.33 459.37
II. ASSETS:
D. Non-Current Assets:
Fixed Assets
i. Tangible Assets 118.37 113.97 125.37 137.81
ii. Intangible Assets 0.98 0.69 0.90 1.08
iii. Capital work-in-progress 19.15 27.10 31.17 34.28
a) Sub-Total Fixed Assets 138.50 141.76 157.43 173.17
b) Non Current Investments 24.97 23.52 24.46 25.93
c) Long Term Loans and Advances 8.15 3.12 3.40 3.67
d) Other non-current assets 2.65 4.06 4.63 5.14
Sub-Total-Non-Current Assets 174.27 172.46 189.92 207.91
E. Current Assets:
a) Inventories 99.19 92.49 100.81 109.28
b) Trade Receivables 125.33 118.35 125.14 132.65
c) Cash and Bank Balances 1.39 0.75 0.90 1.06
d) Short Term Loans and Advances 5.67 4.31 5.11 5.88
e) Other Current Assets 4.35 2.60 2.44 2.59
Sub-Total-Current Assets 235.93 218.50 234.41 251.46
TOTAL-ASSETS (D+E) 410.20 390.96 424.33 459.37
5. Annual Profit & Loss Statement for the period of 2014 to 2017E
Value(Rs.in.mn) FY14A FY15A FY16E FY17E
Description 12m 12m 12m 12m
Net Sales 683.73 649.14 714.05 771.18
Other Income 5.47 4.66 5.22 5.53
Total Income 689.20 653.80 719.27 776.71
Expenditure -663.30 -607.86 -660.50 -713.34
Operating Profit 25.90 45.94 58.77 63.37
Interest -4.29 -3.82 -3.51 -3.69
Gross profit 21.61 42.12 55.26 59.68
Depreciation -9.74 -15.27 -16.49 -17.48
Exceptoional Items 0.00 7.16 0.00 0.00
Profit Before Tax 11.87 34.01 38.77 42.20
Tax -5.92 -10.48 -12.02 -12.87
Net Profit 5.95 23.53 26.75 29.33
Equity capital 49.17 49.17 49.17 49.17
Reserves 179.86 197.08 223.83 253.16
Face value 10.00 10.00 10.00 10.00
EPS 1.21 4.79 5.44 5.96
Quarterly Profit & Loss Statement for the period of 31st Dec, 2014 to 30 Sep, 2015E
Value(Rs.in.mn) 31-Dec-14 31-Mar-15 30-Jun-15 30-Sep-15E
Description 3m 3m 3m 3m
Net sales 151.32 139.05 174.07 193.22
Other income 1.08 1.29 1.46 1.53
Total Income 152.40 140.34 175.53 194.75
Expenditure -145.98 -132.07 -151.49 -178.53
Operating profit 6.42 8.27 24.04 16.22
Interest -0.95 -0.67 -0.76 -0.65
Gross profit 5.47 7.60 23.28 15.57
Depreciation -3.98 -3.65 -3.06 -3.55
Exceptional Items 7.16 0.00 0.00 0.00
Profit Before Tax 8.65 3.95 20.22 12.02
Tax -2.00 -0.97 -7.06 -3.44
Net Profit 6.65 2.98 13.16 8.58
Equity capital 49.17 49.17 49.17 49.17
Face value 10.00 10.00 10.00 10.00
EPS 1.35 0.61 2.68 1.75
7. OUTLOOK AND CONCLUSION
At the current market price of Rs. 89.85, the stock P/E ratio is at 16.52 x FY16E and 15.06 x FY17E
respectively.
Earning per share (EPS) of the company for the earnings for FY16E and FY17E is seen at Rs.5.44 and Rs.5.96
respectively.
Net Sales and PAT of the company are expected to grow at a CAGR of 6% and 5% over 2014 to 2017E
respectively.
On the basis of EV/EBITDA, the stock trades at 7.62 x for FY16E and 7.06 x for FY17E.
Price to Book Value of the stock is expected to be at 1.62 x and 1.46 x for FY16E and FY17E respectively.
We expect that the company surplus scenario is likely to continue for the next three years, will keep its
growth story in the coming quarters also. We recommend ‘BUY’ in this particular scrip with a target price of
Rs.103.00 for Medium to Long term investment.
INDUSTRY OVERVIEW
The Indian pharmaceuticals market is third largest in terms of volume and thirteen largest in terms of value, as
per a pharmaceuticals sector analysis report by equity master. The market is dominated majorly by branded
generics which constitute nearly 70 to 80 per cent of the market. Considered to be a highly fragmented
industry,consolidation has increasingly become an important feature of the Indian pharmaceutical market.
India has achieved an eminent global position in pharma sector. The country also has a huge pool of scientists
and engineers who have the potential to take the industry to a very high level. The UN-backed Medicines Patents
8. Pool has signed six sub-licences with Aurobindo, Cipla, Desano, Emcure, Hetero Labs and Laurus Labs, allowing
them to make generic anti-AIDS medicine Tenofovir Alafenamide (TAF) for 112 developing countries.
The Indian pharmaceutical industry is estimated to grow at 20 per cent compound annual growth rate (CAGR)
over the next five years, as per India Ratings, a Fitch Group company. Indian pharmaceutical manufacturing
facilities registered with US Food and Drug Administration (FDA) as on March 2014 was the highest at 523 for
any country outside the US.
The Union Cabinet has given its approval to amend the existing FDI policy in the pharmaceutical sector in order
to cover medical devices. The Cabinet has allowed FDI up to 100 per cent under the automatic route for
manufacturing of medical devices subject to specified conditions. The drugs and pharmaceuticals sector attracted
cumulative foreign direct investment (FDI) inflows worth US$ 12,813.02 million between April 2000 and
December 2014, according to data released by the Department of Industrial Policy and Promotion (DIPP).
Outlook
The Indian pharma market size is expected to grow to US$ 85 billion by 2020. The growth in Indian domestic
market will be on back of increasing consumer spending, rapid urbanisation, raising healthcare insurance and so
on. Going forward, better growth in domestic sales will depend on the ability of companies to align their product
portfolio towards chronic therapies for diseases such as such as cardiovascular, anti-diabetes, anti-depressants
and anti-cancers are on the rise.
Moreover, the government has been taking several cost effective measures in order to bring down healthcare
expenses. Thus, governments are focusing on speedy introduction of generic drugs into the market. This too will
benefit Indian pharma companies. In addition, the thrust on rural health programmes, life saving drugs and
preventive vaccines also augurs well for the pharma companies.
Disclaimer:
This document is prepared by our research analysts and it does not constitute an offer or solicitation for the
purchase or sale of any financial instrument or as an official confirmation of any transaction. The information
contained herein is from publicly available data or other sources believed to be reliable but we do not represent that
it is accurate or complete and it should not be relied on as such. Firstcall Research or any of its affiliates shall not be
in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the
information contained in this report. Firstcall Research and/ or its affiliates and/or employees will not be liable for
the recipients’ investment decision based on this document.
9. Firstcall India Equity Research: Email – info@firstobjectindia.com
C.V.S.L.Kameswari Pharma & Diversified
U. Janaki Rao Capital Goods
B. Anil Kumar Auto, IT & FMCG
M. Vinayak Rao Diversified
G. Amarender Diversified
Firstcall Research Provides
Industry Research on all the Sectors and Equity Research on Major Companies
forming part of Listed and Unlisted Segments
For Further Details Contact:
Tel.: 022-2527 2510/2527 6077 / 25276089 Telefax: 022-25276089
040-20000235 /20000233
E-mail: info@firstobjectindia.com
www.firstcallresearch.com